ArticleJournal of the American Society of Nephrology : JASN2026
Renal Resistance on Hypothermic Machine Perfusion and Acceptance of Deceased Donor Kidney Allografts.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements inFrontiers in transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsTerminal renal resistance added prognostic value to kidney donor profile index (KDPI), especially in KDPI >0.85 kidneys. Its effect was modest in KDPI ≤0.85 kidneys. Terminal renal resistance was found to be useful in guiding the acceptance of KDPI >0.85 kidneys on the basis of estimated post-transplant survival. Terminal renal resistance ≥0.3 triggered kidney nonuse regardless of KDPI, but KDPI ≤0.85 kidneys should not be declined on the basis of resistance alone.
backgroundElevated terminal renal resistance on hypothermic machine perfusion is widely regarded as a marker of kidney quality and a trigger for kidney nonuse for transplantation, yet large-scale evidence is limited on whether terminal renal resistance adds prognostic value beyond kidney donor profile index (KDPI).
methodsAdult kidney-only transplants performed using hypothermic machine perfusion ( n =36,490) in the Organ Procurement and Transplantation Network database between March 31, 2015, and December 31, 2023, were included. Terminal renal resistance was categorized as <0.2, 0.2-0.3, 0.3-0.4, and ≥0.4 mm Hg/ml per minute. The primary outcome was 5-year graft survival. The association of terminal renal resistance with survival was analyzed to estimate the cutoff renal resistance for accepting high-KDPI (>0.85) kidneys. Utilization analyses were performed in a separate donor cohort of 15,524 kidneys recovered using hypothermic machine perfusion from eight organ procurement organizations.
resultsHigher renal resistance was independently associated with worse 5-year graft survival (hazard ratio for graft loss=1.49 [≥0.4] versus <0.2; P < 0.001). The effect was modest in KDPI <0.35 kidneys and was strongest in KDPI >0.85 grafts. Renal resistance thresholds that were associated with better survival of using KDPI >0.85 kidneys differed on the basis of candidate estimated post-transplant survival (EPTS; renal resistance <0.2 for EPTS <0.35, <0.3 for EPTS 0.35-0.85, and <0.4 for EPTS >0.85). Utilization dropped sharply beyond a terminal renal resistance of 0.3 across all KDPI strata, disproportionate to the actual graft risk. Utilization of KDPI ≤0.85 grafts with renal resistance ≥0.30 could have yielded an estimated 357 (95% confidence interval, 304 to 377) additional transplants per year.
conclusionsTerminal renal resistance was associated with long-term graft and patient survival, but this effect was clinically meaningful only in high-KDPI kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.